GregoryTheGibor
Posted - 47 minutes ago
$GANX i could buy this pig 10x over, the question is, does it have legs? or is this the beginning of the end?
mwb1
Posted - 4 hours ago
$MSTR $BTC.X $IBIT If anyone has taken some profits and wants to diversify like I have: the biotech sector is way oversold and ripe for a turnaround. There are a bunch that have big potential. My favorite is $GANX -- small market cap, high likelihood of disease modifying treatment for Parkinson's and other neurodegenerative diseases. High likelihood of buyout or partnership in the next 6-12 months, with a 10-100X return in the cards. The share price is criminally low right now, and I keep adding. Do some reading about it. It's really an amazing investment opportunity IMO.
microcapspeculator
Posted - 5 hours ago
$GANX More deals in space for preclinical or early stage assets.
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030 - BioSpace
https://www.biospace.com/business/novartis-buys-kate-therapeutics-eyeing-55b-cgt-market-opportunity-by-2030 The Kate acquisition follows Novartis’ potential $745 million license deal with Ratio Therapeutics earlier this week. The partners will collaborate on the preclinical work for an investigational radiotherapy that targets somatostatin receptor 2. Under the terms of the agreement, Novartis can select a candidate to take forward into the clinic, at which point the pharma will take charge of its development.
sratcha
Posted - 6 hours ago
$GANX Wasting my renaing powder supporting this pps from weeks of Jwa68 and his whimsical pump tart text theatrics to where this headed and more like real red toilet fiction....
Again 》 WHERE ARE ISLAM'S or MACK'S FINANCIAL PEOPLE AND WHY AREN'T THEY BUYING!!!😫
Jkpga
Posted - 6 hours ago
$GANX brutal
RealAvidTrader
Posted - 7 hours ago
$GANX ⬇️⬇️⬇️
Jwa68
Posted - 9 hours ago
$GANX Price remains frustrating and severely disconnected from fundamentals. Pendulum always over swings and has been exacerbated by the recent appointment of RFK, an unmerrited over reaction that has depressed small biotech names. Meanwhile M&A is heating up behind the scenes with pharma competing for oncology assets. I expect their attention soon turns to CNS in the new year. There's probably never been a time where an investment here has offered better potential risk vs. reward imo. By the company's own admission, 1B in PD patients has been derisked and we know they have been in ongoing talks with multiple pharma for some time. Value creation in small bio is never linear. If one was desiring to take a long position here, or cover a short position, this is about where I'd consider it. Focus on the data, it speaks for itself. As always, things can change in a split second and often do. Know what you own and do your due diligence. There's never been more of it to assess.
microcapspeculator
Posted - 1 day ago
$GANX New interview.
Drug Discovery World
New vodcast: Joanne Taylor, Gain Therapeutics, at Neuroscience 2024
https://www.ddw-online.com/new-vodcast-joanne-taylor-gain-therapeutics-at-neuroscience-2024-32570-202411/
Dave24689990
Posted - 1 day ago
$GANX The RFK Jr. selection for HHS secretary means that he won't be tapped to lead the FDA, the federal agency with the most influence over the biopharma industry. While biotech leaders may view Kennedy with some trepidation, they’re more optimistic about what a Trump administration might mean for the federal government’s scrutiny of mergers and acquisitions. “With regard to FTC, there’s a good chance that changing leadership there will be a positive for biotech,” Daphne Zohar, the CEO of Seaport Therapeutics and previously head of PureTech Health, wrote in an email. Jonas, of Cure, holds a similar view. “For many of us, our view is the FTC has been very arbitrary in its application of the rules and regulations,” he said. “I think a change at that office will be a benefit to the investment community, to the biotech community and, frankly, for patients and innovation.” https://www.biopharmadive.com/news/trump-election-fda-ftc-drug-biotech-rfk/732194/
TheBehavioralTrader
Posted - 1 day ago
$GANX Still true and price same as when I posted
Being patient for maybe 2nd half 2025
microcapspeculator
Posted - 2 days ago
$GANX Some more info on the upcoming Phase 1b.
Gain Therapeutics(GANX): BTIG Buy $10 PT 11/19/24 P1B Study Design Firmed Up
https://gaintherapeutics.wordpress.com/2024/11/19/gain-therapeuticsganx-btig-buy-10-pt-11-19-24-p1b-study-design-firmed-up/
microcapspeculator
Posted - 2 days ago
$GANX GT-02287 seen to safety enter brain in early Parkinson's clinical trial
https://parkinsonsnewstoday.com/news/gt-02287-safely-enters-brain-early-parkinsons-clinical-trial/
Jwa68
Posted - 2 days ago
$GANX BTIG out with a note reiterating BUY $10 target.
ysroq1
Posted - 2 days ago
$GANX
mwb1
Posted - 2 days ago
$GANX For anyone new or if you need a refresher on what you are holding, see comments for summary and an analysis on likelihood of positive data and resulting market cap estimates. The TLDR version is that there is a ~90% probability that market cap will be valued at 10X - 100X its current level depending on the extent of the positive data in the upcoming 1B.
Jeffg1981
Posted - 2 days ago
$GANX restarted a position- 5k at $1.65
mwb1
Posted - 2 days ago
$GANX Added. And will add more.
marvessa
Posted - 2 days ago
$GANX 43 million market cap and a for many people life changing drug around the corner, what a joke
Jwa68
Posted - 2 days ago
$GANX Thanks for posting.
silkroad58
Posted - 2 days ago
$GANX I can't wait to get out of this black hole. If anyone thinks this will be anything more that a 5$ stock good luck
silkroad58
Posted - 2 days ago
$GANX
microcapspeculator
Posted - 2 days ago
$GANX Latest Chardan Report
Gain Therapeutics(GANX): Chardan November 18th Buy $6 PT. GT-02287 On Track to Commence Phase 1b
https://gaintherapeutics.wordpress.com/2024/11/19/gain-therapeuticsganx-chardan-november-18th-buy-6-pt-gt-02287-on-track-to-commence-phase-1b/
Jwa68
Posted - 2 days ago
$GANX Anyone have a copy of the Chardan report just issued? I just see a note on Bloomberg. Chardan: Gain Therapeutics, Inc. (GANX): GANX (Buy, PT $6): 3Q24 Update. GT-02287 On Track to Commence Phase Ib in 4Q24.
microcapspeculator
Posted - 2 days ago
$GANX What amazes me the most about the recent data is how fast it works. Also the fact it continues to work after stopping seems to indicate a repairing capability. That opens up other areas where damage has occurred and maybe people can be helped.
Jeffg1981
Posted - 3 days ago
$GANX when do they need to raise cash? Is $12mm cash and $4.5mm quarterly opex check out?
Lectin_Pectin
Posted - 3 days ago
$GANX bought more... Didn't think we would be below $2 again. Data continues to be exceptional and I have not seen a single red flag on the science.
Mezacan
Posted - 3 days ago
$GANX
marvessa
Posted - 3 days ago
$GANX crazy that it again is available that cheap
Madmone
Posted - 3 days ago
$GANX This is getting out of hand